Evaluation of PSA Antibody on E9802: Confirmation and Concordance
18 Years
N/A
Male
Prostate Cancer
Trial Information
Evaluation of PSA Antibody on E9802: Confirmation and Concordance
OBJECTIVES:
Primary
- To evaluate changes in prostate-specific antigen (PSA) antibody levels over time among
patients treated on ECOG-E9802.
Secondary
- To characterize the concordance of PSA antibody assessment between the ECOG Immunology
Laboratory and the NCI Immunology Laboratory.
OUTLINE: Previously tested samples are evaluated for changes in PSA antibody levels over
time (from baseline to follow-up at 12 and 24 weeks) at the ECOG Immunology Laboratory and
the NCI Immunology Laboratory. Results are compared between the laboratories.
Inclusion Criteria
DISEASE CHARACTERISTICS: Samples collected on ECOG-E9802 (A Phase II Study of PROSTVAC-V
(Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox/TRICOM with GM-CSF in Patients with PSA
Progression after Local Therapy for Prostate Cancer)
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
PSA antibody levels are compared between baseline and follow-up at 12 weeks, as well as 24 weeks, using Wilcoxon signed-rank test
Safety Issue:
No
Principal Investigator
Robert S. DiPaola, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Cancer Institute of New Jersey
Authority:
Unspecified
Study ID:
CDR0000738979
NCT ID:
NCT01672905
Start Date:
November 2012
Completion Date:
Related Keywords:
- Prostate Cancer
- recurrent prostate cancer
- stage I prostate cancer
- stage IIA prostate cancer
- stage IIB prostate cancer
- stage III prostate cancer
- Prostatic Neoplasms
Name | Location |
|---|
